AstraZeneca loses landmark Losec appeal
This article was originally published in Scrip
The General Court of the European Union has broadly upheld the fine imposed by the European Commission on AstraZeneca for abuse of a dominant position by blocking or delaying generic versions of its proton pump inhibitor, the anti-ulcer drug Losec (omeprazole). The move is expected to give support to the commission in its pursuit of antitrust actions against pharmaceutical companies; the industry federation EFPIA said the ruling could have a "chilling effect" on innovation.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.